



03-30-04

PHA 4254.1 (01258/1/US)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Diane T. Stephenson et al.
Serial No. 10/743,485
Filed December 22, 2003

For COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND
SELECTIVE SEROTONIN REUPTAKE INHIBITORS FOR THE TREATMENT OR
PREVENTION OF A VASO-OCCLUSIVE EVENT

March 29, 2004

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and
in compliance with the duty of disclosure set forth in 37 C.F.R.
* 1.56, applicant submits the attached PTO/SB/08A for consideration
by the Patent and Trademark Office in the above-entitled
application and to be made of record therein. In accordance with
the OG notice of August 5, 2003 partially waiving the
requirements of 37 C.F.R. 1.98(a)(2)(i), copies of the U.S.
patent documents are not supplied. Applicant submits herewith
copies of the foreign patent documents and literature references.

This Information Disclosure Statement is being submitted
pursuant to 37 C.F.R. §1.97(b) in that applicants believe that it
is being filed prior to the mailing date of the first Office
action on the merits. Accordingly, neither a statement nor fee
under 37 C.F.R. §1.97(c) or (d) is required. However, if an
Office action was issued prior to the date of mailing of this

PHA 4254.1 (01258/1/US)
PATENT

Information Disclosure Statement, the Commissioner is hereby authorized to charge any required fees regarding this Information Disclosure Statement to Deposit Account No. 19-1345.


Respectfully submitted,

A handwritten signature in dark ink, appearing to read 'Kathryn J. Doty', written in a cursive style.

Kathryn J. Doty, Reg. No. 40,593
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

KJD/cms

Express Mail Label No. EV416452256US

| | | | | | |
|--|---|----|--------------------------|---------------------|------------|
| PTO/SB/08A | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)  | | | Application Number | 10/743,485 | |
| | | | Filing Date | December 22, 2003 | |
| | | | Confirmation Number | | |
| | | | First Named Inventor | Diane T. Stephenson | |
| | | | Group Art Unit | | |
| | | | Examiner Name | | |
| Sheet | 1 | of | 5 | Attorney Docket No. | PHA 4254.1 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|----------------------|--------------------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | Number | Kind Code ² (if known) | | |
| | 1 | 5,344,991 | | Reitz et al. | 09/06/1994 |
| | 2 | 5,380,738 | | Norman et al. | 01/10/1995 |
| | 3 | 5,393,790 | | Reitz et al. | 02/28/1995 |
| | 4 | 5,434,178 | | Talley et al. | 07/18/1995 |
| | 5 | 5,466,823 | | Talley et al. | 11/14/1995 |
| | 6 | 5,474,995 | | Ducharme et al. | 12/12/1995 |
| | 7 | 5,510,368 | | Lau et al. | 04/23/1996 |
| | 8 | 5,521,207 | | Graneto | 05/28/1996 |
| | 9 | 5,633,272 | | Talley et al. | 05/27/1997 |
| | 10 | 5,932,598 | | Talley et al. | 08/13/1999 |
| | 11 | 6,034,256 | | Carter et al. | 03/07/2000 |
| | 12 | 6,077,850 | | Carter et al. | 06/20/2000 |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | | |
|--|---|----|---|--------------------------|---------------------|
| PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/743,485 |
| | | | | Filing Date | December 22,2003 |
| | | | | Confirmation Number | |
| | | | | First Named Inventor | Diane T. Stephenson |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| Sheet | 2 | of | 5 | Attorney Docket No. | PHA 4254.1 |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|--------------------------|-------------------------|---------------------|--|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | T ⁶ |
| | | Office | Number ⁴ | Kind Code ² (if known) | | | |
| | 13 | WO | 94/13635 | A1 | Merck Frosst Canada Inc. | 06/23/1994 | |
| | 14 | WO | 94/15932 | A1 | G.D. Searle & Co. | 07/21/1994 | |
| | 15 | WO | 94/20480 | A1 | Merck Frosst Canada Inc. | 09/15/1994 | |
| | 16 | WO | 94/26731 | A1 | Merck Frosst Canada Inc. | 11/24/1994 | |
| | 17 | WO | 94/27980 | A1 | G.D. Searle & Co. | 12/08/1994 | |
| | 18 | WO | 95/00501 | A2 | Merck Frosst Canada Inc. | 01/05/1995 | |
| | 19 | WO | 95/15316 | A1 | G.D. Searle & Co. | 06/08/1995 | |
| | 20 | WO | 96/03387 | A1 | G.D. Searle & Co. | 02/08/1996 | |
| | 21 | WO | 96/03388 | A1 | G.D. Searle & Co. | 02/08/1996 | |
| | 22 | WO | 96/06840 | A1 | Merck Frosst Canada Inc. | 03/07/1996 | |
| | 23 | WO | 96/19469 | A1 | Merck Frosst Canada Inc. | 06/27/1996 | |
| | 24 | WO | 96/25405 | A1 | G.D. Searle & Co. | 08/22/1996 | |
| | 25 | WO | 98/03484 | A1 | Merck Frosst Canada Inc. | 01/29/1998 | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | | |
|--|---|----|---|--------------------------|---------------------|
| PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/743,485 |
| | | | | Filing Date | December 22,2003 |
| | | | | Confirmation Number | |
| | | | | First Named Inventor | Diane T. Stephenson |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| Sheet | 3 | of | 5 | Attorney Docket No. | PHA 4254.1 |

| OTHER ART - NON PATENT LITERATURE DOCUMENTS | | | | |
|---|-----------------------|--|----------------|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ | |
| | 26 | ANDRE-PETERSSON et al., "Adaptive Behavior in Stressful Situations and Stroke Incidence in Hypertensive Men", Stroke, 2001, 32: 1712-1720 | | |
| | 27 | BOUCHARD JF, et al., "Mechanisms of Protection Afforded by Cyclooxygenase Inhibitors to Endothelial Function Against Ischemic Injury in Rat Isolated Hearts", Journal of Cardiovascular Pharmacology, 1999 Nov.; 34(5): 755-63 | | |
| | 28 | BYMASTER et al., "Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat", Neuropsychopharmacology, 2002, 27(5): 699-711 | | |
| | 29 | CHALDAKOV, "Proposal for Clinical Trials using Anti-inflammatory Drugs in the Therapy of Angina Pectoris, Myocardial Infarction and Coronary Restenosis after Angioplasty and Bypass Grafting" Medical Hypotheses, 1992, 37: 74-75 | | |
| | 30 | Fibrinolytic Therapy Trialists' "Indications for Fibrinolytic Therapy in Suspected Acute Myocardial Infarction", Lancet, 1994, 343: 311-22 | | |
| | 31 | GIERSE et al., "Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase", Biochem Journal, 1995, 305: 479-84 | | |
| | 32 | GORELICK PB, "Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy", Stroke, 2002, 33:862-875 | | |
| | 33 | GRINSTEAD et al., "Amiprilose in the Prevention of Restenosis After Coronary Intervention in a Swine Model", 1993, Coron Artery Dis, 4: 277-281 | | |
| | 34 | HUANG et al., "Inhibitory effect of curcumin, an anti-inflammatory agent, on vascular smooth muscle cell proliferation", European Journal of Pharmacology, 1992, 221: 381-384 | | |
| | 35 | ISHIWATA et al., "Inhibition of Neointima Formation by Tranilast in Pig Coronary Arteries After Balloon Angioplasty and Stent Implantation", Journal of the American College of Cardiology, 2000, 35: 1331-1337 | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | | |
|--|---|----|---|--------------------------|---------------------|
| PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/743,485 |
| | | | | Filing Date | December 22,2003 |
| | | | | Confirmation Number | |
| | | | | First Named Inventor | Diane T. Stephenson |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| Sheet | 4 | of | 5 | Attorney Docket No. | PHA 4254.1 |

| | | | |
|--|----|---|--|
| | 36 | JORGE et al., "Mortality and Poststroke Depression: A Placebo-Controlled Trial of Antidepressants", American Journal of Psychiatry, 2003, 160(10): 1823-1829 | |
| | 37 | LEE et al., "Prospective Randomized Trial of Corticosteroids for the Prevention of Restenosis After Intracoronary Stent Implantation", American Heart Journal, 1999, 138: 60-63 | |
| | 38 | LOUBINOUX I, et al., "A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects", Neuroimage, 2002 Jan.; 15(1): 26-36 | |
| | 39 | METAIS C, et al., "Serotonin-Induced Coronary Contraction Increases After Blood Cardioplegia-Reperfusion", Circulation, 1999 Nov. 9; 100(19 Suppl): II328-34 | |
| | 40 | METAIS C, et al., "Serotonin-induced human coronary microvascular contraction during acute myocardial ischemia is blocked by COX-2 inhibition", Basic Research in Cardiolgy, 2001 Feb.; 96(1): 59-67 | |
| | 41 | NAPOLI et al., "Inflammation, Hemostatic Markers, and Antithrombotic Agents in Relation to Long-Term Risk of New Cardiovascular Events in First-Ever Ischemic Stroke Patients", Stroke, 2002, 33: 1763-1771 | |
| | 42 | PARIKH et al., "The Impact of Poststroke Depression on Recovery in Activities of Daily Living Over a 2-Year Follow-up" Archives of Neurology, 1990, 47: 785-789 | |
| | 43 | PERRY et al., "Selective Serotonin Reuptak Inhibitors and the Treatment of Affective Illness", Clinical Psychopharmacology Seminar, 1996 | |
| | 44 | POLLOCK BG, et al., "Evaluation of Platelet Activation in Depressed Patients with Ischemic Heart Disease After Paroxetine or Nortriptyline Treatment" J Clin Psychopharmacol, 2000; 20(2): 137-140 | |
| | 45 | RAB et al., "Coronary Aneurysms After Stent Placement: A Suggestion of Altered Vessel Wall Healing in the Presence of Anti-inflammatory Agents" Journal of the American College of Cardiology., 1991, 18: 1524-1528 | |
| | 46 | RIDKER PM, et al., "Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men", New England Journal of Medicine., 1997; 336(14): 973-979 | |
| | 47 | SATO K, et al., "Increased Pulmonary Vascular Contraction to Serotonin After Cardiopulmonary Bypass", Journal of Surgical Research., 2000 May 15; 90(2): 138-43 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | | |
|--|---|----|---|--------------------------|---------------------|
| PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/743,485 |
| | | | | Filing Date | December 22,2003 |
| | | | | Confirmation Number | |
| | | | | First Named Inventor | Diane T. Stephenson |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| Sheet | 5 | of | 5 | Attorney Docket No. | PHA 4254.1 |

| | | | |
|--|----|--|--|
| | 48 | SEREBRUANY VL, et al., "Platelet Inhibition by Sertraline and N-Desmethylertraline", Pharmacological Research, 2001 May; 43(5): 453-62 | |
| | 49 | SINGHAL AB, et al., "Cerebral Vasoconstriction and Stroke After Use of Serotonergic Drugs", Neurology, 2002 Jan 8; 58(1): 130-3 | |
| | 50 | SKOP BP et al., "Potential Vascular and Bleeding Complications of Treatment with Selective Serotonin Reuptake Inhibitors", Psychosomatics, 1996, Jan.-Feb.; 37(1): 12-16 | |
| | 51 | STRECKER et al., "Effect on Intimal Hyperplasia of Dexamethasone Released from Coated Metal Stents Compared with Non-Coated Stents in Canine Femoral Arteries", Cardiovascular and Interventional Radiology, 1998, 21: 487-496 | |
| | 52 | SUGO et al., "Social Stress Exacerbates Focal Cerebral Ischemia in Mice", Stroke, 2002, 33: 1660-1664 | |
| | 53 | VALERO et al., "Intramural Injection of Biodegradable Microspheres as a Local Drug-Delivery System to Inhibit Neointimal Thickening in a Rabbit Model of Balloon Angioplasty" Journal of Cardiovascular Pharmacology, 1998, 31: 513-519 | |
| | 54 | VILA et al., "Proinflammatory Cytokines and Early Neurological Worsening in Ischemic Stroke", Stroke, 2000, 31:2325-2329 | |
| | 55 | YUSUF, et al., "Intravenous and Intracoronary Fibrinolytic Therapy in Acute Myocardial infarction: Overview of Results on Mortality, Reinfarction and Side-Effects from 33 Randomized Controlled Trials", European Heart Journal, 1985, 6:556-85 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.